|
|
|
![]()
1945
Company predecessor, Glucose Corporation, instilled.
Oct. 1962
Company reorganized as Sintong Chemical Industry Company, Limited with $35 million paid-in capitalization as an integrated local pharmaceutical producer.
1979
20ml BFS filler machine procured marking the firm as a premiere local SVP¡] small volume parenteral¡^producer.
1987
* Paid-in capitalization upped to $200 million with IPO completed and passed GMP¡]Good Manufacture Practice¡^inspection.
* Representation of Japan's Nikkiso hemodialysis equipment as the agency embarked on the medical treatment equipment and related field.
* Exports reaching Vietnam to excel Sintong in global expansion.
* Full computerization inducted.
1988
Launched the first bio-equivalent test product in Taiwan, Ranidine, formally certified by the Department of Health.
1989
* Addition of 20ml BFS filling machine.
* Investment in Taiwan Biotech Co., Ltd offering upstream Active Pharmaceutical Ingredients (APIs).
1990
* Technical pact with the Japanese Eisai in jointly producing Aminol-K and the presentation of many of its related products.
* Joint development of transdermal delivery drug system (TDDS) with an U.S.A. Pharmaceutical Development company.
1992
* Accredited with Outstanding Award in the first Outstanding Biotech Awards by the Ministry of Economic Affairs.
* Bestowed with a pilot new product R&D plan for transdermal products sanctioned by the Ministry of Economic Affairs' Bureau of Industrial Development.
1993
* Accredited with an Outstanding Award by the ROC Biotech Industry Development Council.
* Branch office launched at the Hsinchu Science-based Industrial Park.
1994
* Curie Chemicals and Pharmaceuticals Manufacturing Co., Ltd's plant joined Taiwan Biotech's production line in producing oral products.
* The addition of 10ml BFS filler machine.
* API plant certified by the U.S. Food & Drug Administration.
1995 Innovative transdermal nicotine patch, Smokfree, debuted.
1996 AnPo, a labour inhibitors, debuted.
1997 Export of a 20ml BFS¡]Bill-Flow-Seal¡^to Japan began
1998
* Reinvestments made at Huaneng Pharmaceutical Company in Mainland China.
* Dynamics Venture Capital formed in a move to integrate the company's venture investments.
1999
* Represent the U.S. pharmaceutical company, Ocular Sciences' contact lenses.
* Sales and marketing of respiratory system medical equipment, began.
* Investments made to the U.S. company, Optics Corporation, through which TBC's products started to export to the U.S.
2001
* Renamed as Taiwan Biotech Company, Limited.-
* Represent the U.S. pharmaceutical company, Cephalon's Provigil- a narcolepsy treatment solution.-
* Implemented and surpassed the cGMP phase-one review.
2002
* Biotech food manufactory launched at the Hsinchu Science-based Industrial Park.
* Strategic alliance formed with Fresenius Medical Care Corporation of Germany.
2003 Implemented and surpassed the cGMP(II)-process validation review.
2004
* Accredited with pharmaceutical technology research award in the third pharmaceutical technology research awards by the department of health executive yuan.
* Accredited with orphan drug research award in the third orphan drug research awards by the department of health executive yuan.
2005
* Implemented and surpassed the cGMP(III)-computer validation review.
* Accredited with pharmaceutical technology research award in the forth pharmaceutical technology research awards by department of health executive yuan.
* Eye-Cept Rewetting Drops got FDA¡¦s approval of 510(k) for contact lens care products in USA.
* Purchasing the Kuan Yin plant of Fujisawa Pharmaceutical Co., Ltd in Taiwan.
* Acquired management authority of The Veterans Pharmaceutical Plant.
|
| Company: |
Taiwan Biotech Co., Ltd. 信東生技股份有限公司 |
Type: |
Exporter () |
| Area: |
Taiwan |
Size: |
|
| Capital: |
N/A |
Year of registration: |
1962 |
| Verfied: |
|
| Deposit: |
Paid 0.00 USD |
| Business: |
Hemodialysis Products,Respirat,Bone Densitometer,Resuscitation Systems |
| Category: |
|
|
